SCHEMBL3535720

SCHEMBL3535720

Cc1ccc(F)c(NC(=O)Nc2ccc(-c3csc4c(-c5ccc6[nH]ccc6c5)cnc(N)c34)cc2)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 9/20 0.67
BLK P51451 9/20 0.67
CSF1R P07333 8/20 0.67
LYN P07948 8/20 0.67
FLT1 P17948 8/20 0.67
AURKA O14965 8/20 0.67
FGFR1 P11362 8/20 0.67
STK3 Q13188 8/20 0.67
FLT3 P36888 8/20 0.67
PLK4 O00444 7/20 0.67
ABL1 P00519 7/20 0.67
NTRK1 P04629 7/20 0.67
MET P08581 7/20 0.67
ROCK1 Q13464 7/20 0.67
NTRK2 Q16620 7/20 0.67
LCK P06239 7/20 0.67
SRC P12931 7/20 0.67
NEK2 P51955 6/20 0.67
MARK2 Q7KZI7 6/20 0.67
INSR P06213 6/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3533019 0.90 KDR (0.76) KITBLKCSF1RLYNFLT1
SCHEMBL3525534 0.89 BLK (0.67) KITBLKCSF1RLYNFLT1
SCHEMBL1380470 0.88 KDR (0.75) KITBLKCSF1RLYNFLT1
SCHEMBL3530388 0.86 PLK4 (0.76) KITBLKCSF1RLYNFLT1
SCHEMBL1378518 0.86 KDR (0.79) KITBLKCSF1RLYNFLT1
SCHEMBL3532643 0.86 KDR (0.75) KITBLKCSF1RLYNFLT1
SCHEMBL3534099 0.84 KDR (0.76) KITBLKCSF1RLYNFLT1
SCHEMBL3572745 0.84 KDR (0.76) KITBLKCSF1RLYNFLT1
SCHEMBL3526685 0.83 KDR (0.80) KITBLKCSF1RLYNFLT1
SCHEMBL3532104 0.83 PLK4 (0.71) KITBLKCSF1RLYNFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273736-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2012-09-25 US disclosed
US-7737160-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES INC. (US) 2010-06-15 US disclosed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 EP disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 US disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 US disclosed
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK KIT 188/4885BLK 46/4885CSF1R 1197/4885
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK KIT 188/4885BLK 46/4885CSF1R 1197/4885
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KIT 188/4885BLK 46/4885CSF1R 1197/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KIT 188/4885BLK 46/4885CSF1R 1197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.